Xencor upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Xencor (XNCR) to Overweight from Neutral with a price target of $30, up from $20. Xencor is expanding its XmAb technology into autoimmune disease and will report initial Phase I healthy volunteer data on XmAb942 in the first half of 2025, the analyst tells investors in a research note. The firm tells investors to own the shares into the 2025 data.